Abbott Lab's HCV regimen achieves near complete cure rates in mid-stage trial

USA-based Abbott Laboratories (NYSE ABT) announced strong initial results from “Aviator," a Phase IIb study of its interferon-free, investigational regimen for the treatment of hepatitis C (HCV), reporting near complete cure rates in the trial.

Initial results show sustained virological response at 12 weeks post treatment (SVR12) in 99% of treatment-naïve (n=77) and 93% of null responders (n=41) for genotype 1 (GT1) HCV patients taking a combination of ABT-450/r, ABT-267, ABT-333 and ribavirin for 12 weeks, based on an observed data analysis.

Abbott’s shares gained 3.5% to $71.71 in morning New York trading on Monday. Full results from the study will be presented at the Latebreaker Session of The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) in Boston, November 9-13.